Pablo Gonzalez, MD
Hematology & Oncology · Richmond, VANPI 1124080759
Payments from drug & device makers
Across 134 payments — averaging $49.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avyxa Pharma, LLC$4K
- Regeneron Healthcare Solutions, Inc.$542
- Pfizer$361
- Johnson & Johnson$316
- Boehringer Ingelheim International GmbH$220
- E.r. Squibb & Sons, L.L.C.$199
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$2,00031%
- Travel & lodging$1,43422%
- Food & beverage$2,94445%
- Education$971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avyxa Pharma, LLC | 6 | $3,622 |
| Regeneron Healthcare Solutions, Inc. | 17 | $542 |
| Pfizer | 18 | $361 |
| Johnson & Johnson | 12 | $316 |
| Boehringer Ingelheim International GmbH | 1 | $220 |
| E.r. Squibb & Sons, L.L.C. | 10 | $199 |
| US Oncology Corporate, Inc. | 3 | $184 |
| Novartis | 6 | $143 |
| Gilead(2 entities) | 7 | $122 |
| Merck | 6 | $112 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $79 |
| AstraZeneca | 4 | $71 |
| Astellas Pharma US Inc | 4 | $70 |
| Seagen Inc. | 3 | $70 |
| EMD Serono, Inc. | 3 | $62 |
| Array Biopharma Inc | 4 | $51 |
| Ipsen Biopharmaceuticals, Inc | 3 | $49 |
| Puma Biotechnology, Inc. | 2 | $35 |
| Legend Biotech USA Inc. | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| GSK | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Bayer | 1 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$368
How this compares
$6,695 in reported general payments places this provider in the 60th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 68 | $995,742 |
| PomalystPomalidomide | 31 | $681,419 |
| CalquenceAcalabrutinib Maleate | 40 | $573,516 |
| CabometyxCabozantinib S-Malate | 22 | $537,214 |
| VenclextaVenetoclax | 16 | $241,861 |
| InlytaAxitinib | 11 | $222,015 |
| TagrissoOsimertinib Mesylate | 13 | $215,488 |
| XtandiEnzalutamide | 12 | $161,429 |
| InqoviDecitabine/Cedazuridine | 13 | $107,397 |
| XareltoRivaroxaban | 89 | $81,581 |
| EliquisApixaban | 49 | $46,065 |
| Imatinib Mesylate | 12 | $11,006 |
| Exemestane | 12 | $2,477 |
| Acyclovir | 45 | $1,543 |
| Dexamethasone | 32 | $734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $79 | $995,74268 claims |
| AstraZenecaCalquence, Tagrisso | $71 | $789,00453 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $199 | $681,41931 claims |
| PfizerInlyta, Eliquis | $361 | $268,08160 claims |
| Astellas Pharma US IncXtandi | $70 | $161,42912 claims |
| Taiho Oncology, Inc.Inqovi | $24 | $107,39713 claims |
| Johnson & JohnsonXarelto | $316 | $81,58189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Richmond
- Erin AlesiRichmond$1.7M
- Sarah GordonRichmond$1M
- Will VoelzkeRichmond$774K
- James KhatcheressianRichmond$773K
- Victor YazbeckRichmond$756K
- William ClarkRichmond$685K
- Elke FriedmanRichmond$571K
- Joshua McFarlaneRichmond$390K
- Jonathan BerkmanRichmond$360K
- Reed MitchellRichmond$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.